Page 937«..1020..936937938939..950960..»

Pharmaceutical and Biotechnology Machines Market: How the Business Will Grow in 2027? – Apsters News

Posted: July 9, 2020 at 2:50 am

The Pharmaceutical and Biotechnology Machines Market Analysis to 2027 is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of pharmaceutical and biotechnology machines market with detailed market segmentation by of product and end user/application. The pharmaceutical and biotechnology machines market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in pharmaceutical and biotechnology machines market and offers key trends and opportunities in the market.

Some of the key players profiled in the study are Air Liquide, Atlas Copco AB, Beijing Orient, Linde Healthcare, Messer Group, Nanning Lantian, Shenwei Medical, Shenzhen Gaofa, Sicgil India Limited, SOL Group, Taiyo Nippon Sanso, etc.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00011795/

What is Pharmaceutical and Biotechnology Machines Market?

The biotechnology machine is for process Separations. Also, process-scale separation systems, mainly high-volume chromatography systems, are among the most crucial biotechnology machine in the modern biopharmaceutical industry. Its applications of process chromatography include recombinant protein purification. Pharmaceutical biotechnology refers to the use of biotechnology for manufacturing drugs, gene therapy as well as gene testing. This is done by manipulating and modifying organisms, usually at the molecular level.

The pharmaceutical and biotechnology machines market is propelling due to advancement of technology and rising geriatric population. However, the high cost of devices, stringent regulations, and lack of skilled personnel hamper the market growth.

The pharmaceutical and biotechnology machines market is segmented on the basis of product and end user/application. Based on product, the market is segmented as oxygen, nitrous oxide, medical air and others(nitrogen, carbon dioxide and helium). On the basis of end user/application, the market is categorized as hospitals (labs and clinics), home healthcare, universities/research institutions and pharmaceutical and biotechnology industries.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted Price @ https://www.theinsightpartners.com/discount/TIPRE00011795/

Key questions answered by this report:

Our reports will help clients solve the following issues:

Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Evaluating potential business partners:

Our research and insights help our clients identify compatible business partners.

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00011795/

Pharmaceutical and Biotechnology Machines Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Read the original:
Pharmaceutical and Biotechnology Machines Market: How the Business Will Grow in 2027? - Apsters News

Posted in Biotechnology | Comments Off on Pharmaceutical and Biotechnology Machines Market: How the Business Will Grow in 2027? – Apsters News

Analysis of Potential Impact of COVID-19 on White Biotechnology Market – Cole of Duty

Posted: July 9, 2020 at 2:50 am

The globalwhite biotechnology marketis highly consolidated, as key players are holding 71% share in the global market, reports Transparency Market Research. Prominent players in the market are investing heavily in research and development activities in order to produce effective and better results. These players are also investing in mergers and acquisition, collaboration, partnership, and innovation to get a stronger hold in the market. Apart from key players, few small and medium players are also engaging in these strategies mainly to maintain their position in the market. In this report, researchers have analyzed few leading players including Cargill Inc., Archer Daniels Midland Company, DuPont, BASF SE, and Novozymes.

As per TMRs report, the global white biotechnology market is expected to rise at 4.50% CAGR over the projected tenure between 2016 and 2024. If the market progresses at this rate, the markets revenue is likely to reach US$262.3 bn by the end of 2024. In 2015, the market earned US$ US$178.1 bn.

On the basis of product, the demand in the biofuel segment is high. In 2015, this segment held 31.16% share in the global white biotechnology market. Over the forecast period, this segment is likely to maintain its position. In terms of application, others segment is expected to lead the global market. On the regional front, North America to hold maximum share in the global white biotechnology market. Increasing funding from government for research and development activities in the field of white biotechnology has fueled demand in North America white biotechnology market

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) :https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2317

Increasing Government Support to Benefit Growth in White Biotechnology

Rising government initiatives to promote white biotechnology is one of the major factor driving demand in the global white biotechnology market. In addition, white technology is also environment friendly and produces low waste by using efficient methods of production. The white biotechnology cannot be compared with oil and crop prices, as the prices of this technology keep on fluctuating rapidly. Furthermore, growing need from various consumer industries such as consumer goods and automotive to meet sustainability targets is projected to augment technology demand over the projected period.

Adding further to the growth factors, increasing government support to growth of white biotechnology through research and development activities and schemes are also expected to expand growth opportunities for the global white biotechnology market. Moreover, increasing demand for green chemicals in developed regions who are ready to pay higher prices for renewable products will further accelerate demand in this market.

REQUEST FOR COVID19 IMPACT ANALYSIS https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2317

Deteriorating Fertility of Agricultural Lands Might Hamper Growth in White Biotechnology Market

The key challenge that might hamper the growth in the global white biotechnology market includes deteriorating fertility of agricultural lands. This takes place due to over and misuse of fertilizers upon crops that resulted in depleting fertility from agricultural lands. Due to over utilization of fertilizers, the prices of bio-crops have been fluctuated, as there was uncertainty of production yield of bio-crops. Moreover, use of traditional foods and fuels by customers is also expected to hamper growth in the global white biotechnology market.

The study presented here is based on a report by Transparency Market Research (TMR) titled White Biotechnology Market (Product Biochemical, Biofuel, Biomaterial, Bioproduct; Application Food and Feed, Pharmaceuticals, Pulp and Paper, Textile, Energy; Feedstock Grains and Starch Crops, Agricultural Residues, Food Waste, Forestry Material, and Animal) Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 2024.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

The global white biotechnology market is segmented based on:

Product

Application

Feedstock

Regional

More Trending Reports by Transparency Market Research 1.https://www.prnewswire.com/news-releases/global-chronic-obstructive-pulmonary-disease-copd-treatment-market-to-reach-us-26-2-bn-in-2027-drug-makers-focus-on-combination-therapies-transparency-market-research-301011476.html

2.https://www.biospace.com/article/peptide-therapeutics-market-to-experience-extensive-growth-thanks-to-rising-demands-for-improved-healthcare/

Read the rest here:
Analysis of Potential Impact of COVID-19 on White Biotechnology Market - Cole of Duty

Posted in Biotechnology | Comments Off on Analysis of Potential Impact of COVID-19 on White Biotechnology Market – Cole of Duty

MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO -…

Posted: July 9, 2020 at 2:50 am

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on development of first-in-class drugs, announced today that encouraging preclinical results supporting newly-identified immunogenic effects of the companys lead product candidate, investigational THIO (6-thio-dG), the only telomere-by-telomerase targeting agent in development for the treatment of cancer, has been published in Cancer Cell, a renowned peer-reviewed scientific journal covering major advances in cancer research. The manuscript entitled: Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity, Mender et al., is now featured online and will also be published in the September 2020 edition of Cancer Cell, Volume 38, pages 1-12.

Telomerase is the enzyme responsible for the maintenance of telomeres. While inactive in most normal cells, telomerase is activated in the majority of cancer cells, making it an attractive target for cancer therapy. Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage. The latest preclinical data showed this is complemented by an immunogenic effect, which may allow for more durable outcomes when used sequentially with immunotherapy. THIOs activity was shown to be cancer-specific in tumor types with active telomerase. Since up to 35 million patients have telomerase-positive cancers, MAIA Biotech believes these results suggest that THIO holds significant potential to treat large patient populations across many types of cancers.

In these preclinical studies published in Cancer Cell, investigators demonstrated that THIO leads to tumor regression through induction of innate and adaptive host immune system responses. THIO was shown to be directly incorporated into telomeres by telomerase, where it rapidly induced telomeric DNA damage responses, which is selective to telomerase-positive TERT(+) cancer cells without affecting normal telomerase-silent cells. The findings also indicated that THIO induces DNA-mediated innate sensing and activation of immune responses in a host cGAS/STING-dependent manner, leading to improved anti-tumor efficacy. Low doses of THIO, followed by anti-PD-L1 therapy, completely eliminated advanced tumors in preclinical models and produced cancer cell specific immune memory where the immune system continued to be active against the cancer cells after extended periods of time with no additional treatment. These results are significant as they demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining telomere-targeted therapy with immunotherapy.

We believe THIO has the potential to transform the immuno-oncology landscape and change the cancer treatment paradigm, and these most recent findings provide a strong rationale for combining telomere-targeted therapy with immunotherapy, stated Vlad Vitoc, MD, MAIAs Chief Executive Officer and President. We believe the publication of these unprecedented immunogenic effects of THIO in Cancer Cell provides additional validation for this innovative program. We are highly encouraged by these promising findings of tumor elimination, cancer specific immune responses, and stimulation of immune memory, which build upon prior positive preclinical results. These findings provide further support for the companys plans to advance THIO into Phase 1 clinical studies in 2021.

About THIO

THIO (6-thio-dG) is a small molecule in preclinical development and is the only telomere-by-telomerase targeting agent currently in development. THIO is designed to selectively kill cancer cells by modifying telomeric DNA structure and function utilizing telomerase. Telomerase is present in >85% of human cancers and contributes significantly to proliferation and immortality of cancer cells. THIO is recognized by telomerase and incorporated into telomeres selectively in cancer cells. Once incorporated, it compromises the telomere structure and function, leading to uncapping of the chromosome ends and thus resulting in rapid tumor cell death. In preclinical studies, this rapid cancer cell death occurred without impacting normal cells. THIO is investigational and has not been approved for any use anywhere in the world.

About Cancer Cell

Cancer Cell provides a high-profile forum to promote major advances in cancer research and oncology. The primary criterion for considering manuscripts is whether the studies provide major advances into answering important questions relevant to naturally occurring cancers. Cancer Cell is also interested in publishing clinical investigations, in particular those that lead to establishing new paradigms in the treatment, diagnosis, or prevention of cancers; those that provide important insights into cancer biology beyond what has been revealed by preclinical studies; and those that are mechanism-based proof-of-principle clinical studies. For more information, please visit http://www.cell.com/cancer-cell or follow the journal on Twitter: @Cancer_Cell.

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. MAIAs business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure. Drug candidates include (i) THIO, a telomere-by-telomerase targeting agent in preclinical development for the treatment of telomerase positive cancer cells; (ii) GMC1, a FKBP52 co-chaperone-inhibitor being evaluated for prostate cancer and breast cancer; and (iii) MJC13 is a drug candidate with a potentially novel mode of action targeting androgen receptor (AR) inhibition that is important in prostate and breast cancers. MAIA is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into clinical trials. For more information, please visit http://www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industrys actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as may, might, will, should, could, expect, plan, anticipate, believe, estimate, project, intend, future, potential or continue, and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, MAIA, Company, we, our, and us refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005271/en/

Read more here:
MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO -...

Posted in Biotechnology | Comments Off on MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO -…

Pharmaceutical and biotechnology Segment to be the Most Lucrative in Chromatography Systems Market – Jewish Life News

Posted: July 9, 2020 at 2:50 am

There is an unexpected shift in the world, and many sectors are experiencing thoughts triggered by the COVID-19 pandemic. The outbreak of COVID-19 has had a positive impact on the demand for chromatography. In the pharmaceutical industry, chromatography technology is commonly used for the detection of cancer cells. It is also used for drinking water and air processing, plasma fractionation, enzyme purification, and purification. The Environmental Authority, for example, listed chromatography as safe for the measurement of drinking water purity as a means of easy propagation of the coronavirus through polluted water. During this coronavirus crisis, we are helping our clients in understanding the impact of COVID-19 on the chromatography system market.

Our report includes:

A new report by Research Dive states that the global chromatography system market is set to grow at a CAGR of 6.9% and is projected to garner a revenue of $16,304.0 million during the period of forecast from 2019 to 2026. The report delivers in-depth insights into opportunities, vital segments, restraints, drivers, and prominent players of the global market. Based on the type, end-use, and region of the global market segmentation. The report offers insights on drivers, opportunities, restraints, analysis of segment, and competitive market players. Increasing the use of chromatography methods in the pharmaceutical industry is a significant factor for market growth, according to our analysts. Nonetheless, due to the existence of capillaries for the oxygen, hydrogen, and methane separation, a requirement of qualified professionals and high construction costs and maintenance costs is anticipated to impede the growth of the market for the chromatography device. The global market is segmented on the basis of type, end-use industry, and region.

Check out How COVID-19 impact on the Chromatography Systems Market. Click here to Connect with Analyst @ https://www.researchdive.com/covid-19-insights/207/chromatography-system-market#myQueryForm

Pharmaceutical and biotechnology Segment to be the Most Lucrative

The chromatography device market is categorized on the basis of end-use application into hospitals and medical, pharmaceutical, and biotechnology industries and the food and agriculture industry. The demand for pharmaceuticals and biotechnology is projected to rise by 7.3% CAGR, with $5,651.4 million anticipated by 2026. The need for highly sensitive product information in terms of quality and purity, increased use of biopharmaceuticals, especially bio-similar medicines, and monoclonal antibodies that are expected to drive the need for chromatography system are all contributing to the size of the market in the prediction time frame.

The world market share for Asia-Pacific is prominent and is projected to hit $3,283.9 million by 2026 @ https://www.researchdive.com/covid-19-insights/207/chromatography-system-market

Asia-Pacific Region to Expand Business at a Considerable Growth Rate

The world market share for Asia-Pacific is prominent and is projected to hit $3,283.9 million by 2026. The rise in research activities in different fields, such asbiological innovation and pharmaceutical purpose, has contributed to this dominance. A substantial increase is expected to result in sales of $3,283.9 million by 2026, with a 7.5% CAGR in demand for Asia-Pacific RO water treatment system components. In Asia-Pacific, this anticipated rise is mainly due to the existence, of several biopharmaceutical research and development centres, in various major companies such as Merck, Eli Lilly, and Pfizers. These factors are anticipated to fuel the growth of the market over time.

Prominent Players of the Market

Some of the key players of the global chromatography system market include Agilent Technologies (NYSE: A), Perkin Elmer, APIX, Thermo Fisher Scientific Inc., Xylem (OI Analytical), CDS Analytical, Shimadzu Corporation, Waters Corporation, Jasco Inc, Bio-Rad Laboratories and others. These players are adopting several strategies such as mergers & acquisitions and novel product developments to improve their company position in the global industry.

About Us:Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact us:Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US)Toll Free: +1-888-961-4454E-mail: [emailprotected]LinkedIn:https://www.linkedin.com/company/research-dive/Twitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-Dive-1385542314927521Blog:https://www.researchdive.com/blogFollow us:https://marketinsightinformation.blogspot.com/

Read more:
Pharmaceutical and biotechnology Segment to be the Most Lucrative in Chromatography Systems Market - Jewish Life News

Posted in Biotechnology | Comments Off on Pharmaceutical and biotechnology Segment to be the Most Lucrative in Chromatography Systems Market – Jewish Life News

Is Immunomedics, Inc. (IMMU) a Winner in the Biotechnology Industry? – InvestorsObserver

Posted: July 9, 2020 at 2:50 am

A rating of 80 puts Immunomedics, Inc. (IMMU) near the top of the Biotechnology industry according to InvestorsObserver. Immunomedics, Inc.'s score of 80 means it scores higher than 80% of stocks in the industry. Immunomedics, Inc. also received an overall rating of 70, putting it above 70% of all stocks. Biotechnology is ranked 13 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 70 would rank higher than 70 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Immunomedics, Inc. (IMMU) stock is trading at $41.15 as of 1:12 PM on Monday, Jul 6, an increase of $3.61, or 9.62% from the previous closing price of $37.54. The stock has traded between $39.22 and $41.40 so far today. Volume today is 3,753,250 compared to average volume of 3,897,633.

To see the top 5 stocks in Biotechnology click here.

Follow this link:
Is Immunomedics, Inc. (IMMU) a Winner in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Immunomedics, Inc. (IMMU) a Winner in the Biotechnology Industry? – InvestorsObserver

Vir Biotechnology, Inc. (VIR) Plans and Analysts Expectations – The News Heater

Posted: July 9, 2020 at 2:49 am

Vir Biotechnology, Inc. (NASDAQ:VIR) went up by 1.74% from its latest closing price when compared to the 1-year high value of $75.00 and move down -82.84%, while VIR stocks collected +5.64% of gains with the last five trading sessions. Press Release reported 17 hours ago that Vir Biotechnology Announces Proposed Public Offering of Common Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) 2 of the analysts out of 5 who provided ratings for Vir Biotechnology, Inc. stocks as a buy while 0 as overweight, 1 rated it as hold and 1 as sell. The average price we get from analysts is $32.50 which is -$6.35 below current price. VIR currently has a short float of 2.80% and public float of 99.67M with average trading volume of 1.65M shares.

VIR stocks went up by 5.64% for the week, with the monthly jump of 20.61% and a quarterly performance of 41.45%. The simple moving average for the period of the last 20 days is 7.60% for VIR stocks with the simple moving average of 62.80% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -45.31% of loss for the given period.

The stock volatility was left at 9.77%, however, within the period of a single month, the volatility rate increased by 9.02%, while the shares surge at the distance of +23.52% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +31.69% upper at the present time.

In the course of the last 5 trading sessions, VIR went up by +5.64%, in comparison to the 20-day moving average settled at $38.51. In addition, Vir Biotechnology, Inc. saw 226.20% in overturn over the period of a single year with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at Vir Biotechnology, Inc. (VIR), starting from Horn Howard, who sold 10,000 shares at the price of $40.00 back on Jul 02. After this action, Rushing now owns 207,777 shares of Vir Biotechnology, Inc., valued at $400,000 with the latest closing price.

Parrish Jay, the Chief Business Officer of Vir Biotechnology, Inc., sold 75,000 shares at the value of $37.95 during a trade that took place back on Jul 01, which means that Parrish Jay is holding 222,222 shares at the value of $2,846,310 based on the most recent closing price.

The current profitability levels are settled at -2144.35 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -62.52, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

Read the rest here:
Vir Biotechnology, Inc. (VIR) Plans and Analysts Expectations - The News Heater

Posted in Biotechnology | Comments Off on Vir Biotechnology, Inc. (VIR) Plans and Analysts Expectations – The News Heater

GlobalBiotechnology Separation Systems Market Report 2020 Sales Forecast to Grow Negatively in Western Regio post COVID 19 Impact Analysis Updated…

Posted: July 9, 2020 at 2:49 am

Global Biotechnology Separation Systems Market analysis 2015-2027, is a research report that has been compiled by studying and understanding all the factors that impact the market in a positive as well as negative manner. Some of the prime factors taken into consideration are: various rudiments driving the market, future opportunities, restraints, regional analysis, various types & applications, Covid-19 impact analysis and key market players of the Biotechnology Separation Systems market. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Download Report from: https://cognitivemarketresearch.com/machinery-%26-equipment/biotechnology-separation-systems-market-report

Global Biotechnology Separation Systems Market: Product analysis: Membrane Filtration, Chromatography, Centrifuge, Electrophoresis, Flow Cytometry, Others

Global Biotechnology Separation Systems Market: Application analysis: Commercial, Scientific Research

Major Market Players with an in-depth analysis: Danaher, Thermo Fisher Scientific, BD, Merck, GE Healthcare, Agilent, Sysmex, Alfa Wassermann, Shimadzu, Sartorius Stedim Biotech, Illumina, Waters, Novasep, 3M Purification, Affymetrix, Bio Rad Laboratories, Alfa Laval, PerkinElmer, Repligen, Hitachi Koki

The research is presented in such a way that it consists of all the graphical representations, pie charts and various other diagrammatic representations of all the factors that are used for the research. Biotechnology Separation Systems market research report also provides information on how the industry is anticipated to provide a highly competitive analysis globally, revenues generated by the industry and increased competitiveness and expansions among various market players/companies.

Get A Free Sample of Biotechnology Separation Systems Market Report: https://cognitivemarketresearch.com/machinery-%26-equipment/biotechnology-separation-systems-market-report#download_report

The Biotechnology Separation Systems industry is projected in assembling information regarding dynamic approximations and also listings of a profitable progression rate annually in the expected duration according to a recent & latest study. The latest Coronavirus pandemic impact along with graphical presentations and recovery analysis is included in the Biotechnology Separation Systems research report. The research report also consists of all the latest innovations, technologies and systems implemented in the Biotechnology Separation Systems industries.

Various factors with all the necessary limitations, expenditure/cost figures, consumer behaviour, supply chain, government policies and all the information related to the market have been included in the Biotechnology Separation Systems Market report. The research report also provides light on various companies & their competitors, market size & share, revenue, forecast analysis and all the information regarding the Biotechnology Separation Systems Market.

Checkout Inquiry for Buying or Customization of Report: https://cognitivemarketresearch.com/machinery-%26-equipment/biotechnology-separation-systems-market-report#download_report.

Biotechnology Separation Systems Market research report provides an in-depth analysis of the entire market scenario starting from the basics which is the market introduction till the industry functioning and its position in the market as well as all the projects and latest introductions & implementations of various products. The research study has been assembled by understanding and combining various analysis of regions globally & companies and all necessary graphs and tables that bring the theory into an exact representation through numerical values and standard tables.

The global estimations of the market value, market information/definition, classifications of all the types & applications, overall threats & dips that can be assumed and many other factors which consist the overall market scenario and its happening globally along with the forthcoming years are compiled in the Biotechnology Separation Systems market research report. Hence this report can serve as a handbook/model for the enterprises/players interested in the Biotechnology Separation Systems Market as it consists all the information regarding the Biotechnology Separation Systems market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Biotechnology Separation Systems Market Report 2020 (Coronavirus Impact Analysis on Biotechnology Separation Systems Market)

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.(*If you have any special requirements, please let us know and we will offer you the report as you want.)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: nicolas.shaw@cognitivemarketresearch.comWeb: https://www.cognitivemarketresearch.com/

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/machinery-%26-equipment/biotechnology-separation-systems-market-report

Read the original post:
GlobalBiotechnology Separation Systems Market Report 2020 Sales Forecast to Grow Negatively in Western Regio post COVID 19 Impact Analysis Updated...

Posted in Biotechnology | Comments Off on GlobalBiotechnology Separation Systems Market Report 2020 Sales Forecast to Grow Negatively in Western Regio post COVID 19 Impact Analysis Updated…

Asia Pacific Next Generation Sequencing Market is expected to reach US$ 5835.6 Million by 2027 with CAGR of 21.8%. – Cole of Duty

Posted: July 9, 2020 at 2:49 am

Next Generation Sequencing, Massively Parallel or Deep Sequencing is related terms for DNA sequencing technology that revolutionized genomics research. NGS allows you to sequence the entire human genome in one day. According to the report by Business Market Insights, Asia Pacific Next Generation Sequencing Marketis expectedto reach US$ 5,835.6 Million by 2027 with CAGR of 21.8%.

Biotechnology is technology that utilizes biological systems, living organisms or parts of this to develop or create different products. Brewing and baking bread are examples of processes that fall within the concept of biotechnology (use of yeast (= living organism) to produce the desired product).

The Asia Pacific Next Generation Sequencing Marketis growing along with the Biotechnology industry, but the market is likely to slow down its growth due to the shortage of skilled professionals, suggests the Business Market Insights report.

The Business Market Insights subscription helps clients understand theon-goingmarket trends,identifyopportunities, and make informed decisions through the reports in the Subscription Platform. The Industry reports available in the subscriptionprovidean in-depth analysis on various market topics and enable clients to line up remunerative opportunities. The reportsprovidethe market size & forecast, drivers, challenges, trends, and more.

Get free trial subscription and gain instant access to our market research reports at https://www.businessmarketinsights.com/TIPRE00005751/request-trial

Advancement in the field of molecular biology has equally enhanced the sequencing procedures. Many industry players have come up with innovative NGS technology in last few years. Further modification and automation of this process continued to increase sequencing data and time reduction. There by allowing researchers to reach major milestones in the Human Genome Project. NGS makes sequence based gene expression analysis a digital alternative to analog techniques. It also aids in quantifying RNA expression with the breadth of a microarray and the resolution of PCR.

For instance, in January 2018, Illumine, Inc. launched their Base Space Sequence Hub in China. The cloud-based hub has facilities for storage management, and interpretation of genomics data. Similar initiatives and developments in the region are likely to accelerate the market growth of next generation sequencing over the coming years.

These factorsare expectedto offer broad growth opportunities in the Biotechnology industry and this is expected to cause the demand forimmunochemistryassays in the market.

Business Market Insights reports focus upon clientobjectives, use standard research methodologies and exclusive analytical models, combined with robust business acumen, which providesprecise and insightful results.

Business Market Insights reports are usefulnot only forcorporate and academic professionalsbut also forconsulting, research firms,PEVCfirms, and professional services firms.

Asia Pacific Next Generation Sequencing MARKET SEGMENTATION

By Product

By Technology

By Application

By End User

By Geography

Company Profiles

Full Report subscription with pay as per requirement at https://www.businessmarketinsights.com/TIPRE00005751/checkout/basic/single/monthly

(30-day subscription plans proveto beverycost-effectivewith no compromise on the quality of reports)

Benefits with Business Market Insights

About Business Market Insights

Based in New York, Business Market Insights is a one-stop destination for in-depth market research reports from various industries including Technology, Media & Telecommunications, Semiconductor & Electronics, Aerospace & Defense, Automotive & Transportation, Biotechnology, Healthcare IT, Manufacturing & Construction, Medical Device, and Chemicals & Materials. The clients include corporate and academic professionals, consulting, research firms,PEVCfirms, and professional services firms.

For Subscription contact

Business Market Insights

Phone :+442081254005E-Mail :[emailprotected]

Read the original here:
Asia Pacific Next Generation Sequencing Market is expected to reach US$ 5835.6 Million by 2027 with CAGR of 21.8%. - Cole of Duty

Posted in Biotechnology | Comments Off on Asia Pacific Next Generation Sequencing Market is expected to reach US$ 5835.6 Million by 2027 with CAGR of 21.8%. – Cole of Duty

ACMG’s Genetics in Medicine Journal Receives Impact Factor of 8.904 for 2019–Journal is Ranked 13th of 177 Journals in Genetics & Heredity -…

Posted: July 9, 2020 at 2:48 am

BETHESDA, Md., July 8, 2020 /PRNewswire/ --The American College of Medical Genetics and Genomics (ACMG) announced today that the 2019 Journal Impact Factors, published by Clarivate Analytics in the latest edition of Journal Citation Reports, calculated an impact factor of 8.904 for ACMG's official journal, Genetics in Medicine (GIM). This is the second highest Impact Factor in the journal's history and ranks GIM 13th of 177 titles in the Genetics & Heredity category.

The Impact Factor is an objective measure of the world's leading journals, based on articles' cited references and is oft considered a measure of a journal's impact, overall successful performance and relevance to its field. The most highly cited article in GIM in 2019 was "Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (ACMG SF v2.0): A Policy Statement of the American College of Medical Genetics and Genomics."

"GIM's editors and editorial staff are delighted that our Impact Factor has increased from last year. This improvement in the Impact Factor once again demonstrates that the journal remains one of the most widely read and cited journals publishing clinically relevant research in the life sciences," said GIM's Editor-in-Chief Robert D. Steiner, MD, FAAP, FACMG."We are most thankful to the peer reviewers who put in countless hours to help maintain the outstanding quality of articles and the authors who trust us to disseminate their groundbreaking scholarly work. The Impact Factor is one of a number of metrics used to evaluate journals, and a journal should not be evaluated solely on that one metric. Genetics in Medicine'scontinued success and relevance is also reflected in our very high overall downloads and reads as well as a prominent social media presence."

ACMG CEO Maximilian Muenke, MD, FACMG said, "As the CEO of the ACMG, I am extremely proud of 'our' journal. As a physician-scientist who before joining ACMG worked in academic settings where publishing in high-impact factor journals was the goal, I am well aware of the importance of this metric. My congratulations and gratitude on increasing GIM's impact factor go to Bob Steiner, Jan Higgins, the GIM staff and the entire editorial team to make this success happen!"

Genetics in Medicineis published by Springer Nature. The journal, published since 1998, is supported by an expert board of editors representing all facets of genetic and genomic medicine, including biochemical and molecular genetics, cytogenetics, and the application of genetics and genomics to other medical specialties such as oncology, cardiology, neurology, pediatrics, ophthalmology and maternal-fetal medicine.

About the American College of Medical Genetics and Genomics (ACMG) and ACMG Foundation

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical professional organization solely dedicated to improving health through the practice of medical genetics and genomics, and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,300 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Kathy Moran, MBA[emailprotected]

SOURCE American College of Medical Genetics and Genomics

http://www.acmg.net

Read more here:
ACMG's Genetics in Medicine Journal Receives Impact Factor of 8.904 for 2019--Journal is Ranked 13th of 177 Journals in Genetics & Heredity -...

Posted in Molecular Genetics | Comments Off on ACMG’s Genetics in Medicine Journal Receives Impact Factor of 8.904 for 2019–Journal is Ranked 13th of 177 Journals in Genetics & Heredity -…

July 2020: New NIEHS Director Rick Woychik will lead with innovation – Environmental Factor Newsletter

Posted: July 9, 2020 at 2:48 am

National Institutes of Health (NIH) Director Francis Collins, M.D., Ph.D., announced selection of Richard (Rick) Woychik, Ph.D., to serve as director of NIEHS. Woychik was acting director of NIEHS from October 2019 until June 7, the official start of his new role.

Innovation has been a hallmark of Ricks scientific career and its at the center of his vision for leading NIEHS, said Collins. He will be working to support new technologies and scientific approaches throughout the field of environmental health sciences applying his proven skills in scientific excellence, creativity, and rigor to improving public health.

As NIEHS director, Woychik takes on additional responsibility as director of the National Toxicology Program (NTP), which reports directly to the U.S. Department of Health and Human Services. NTP coordinates toxicology research among NIEHS, the National Center for Toxicological Research at the U.S. Food and Drug Administration, and the National Institute for Occupational Safety and Health at the Centers for Disease Control and Prevention.

Woychik is highly respected for a long list of accomplishments in environmental epigenetics and mammalian genetics. His laboratory discovered that mutations in a gene that codes for a protein in a class called protocadherins interfered with mammalian hearing. This gene was ultimately linked to hearing loss in Cushings disease patients.

Other firsts included identifying a gene associated with polycystic kidney disease, and the first cloning of an obesity-related gene called agouti. Woychiks passion for epigenetics and environmental health sciences is rooted in his research groups discovery that the obesity trait associated with an agouti mutant mouse line was influenced during embryonic development by the epigenome.

Woychik said he will explore opportunities to embrace new technologies and implement state-of-the-art and potentially transformative scientific approaches for the NIEHS research enterprise. I am particularly interested in better integrating environmental health sciences into the All of Us Research Program and Precision Medicine programs at NIH, he wrote in an email to employees.

He added that achieving insights into the molecular mechanisms of toxicity and other physical responses to environmental exposures will be fundamental to improving risk assessments of human health impacts.

Individuals, with their unique biological make-up, respond to the environment in different ways. Our current research strategies mostly employ a one-size-fits-all approach that does not factor in this critically important variable, Woychik explained. One important element of my vision for the institute is to deal with individual genetic, epigenetic, and biological variability when establishing research strategies for studying public health and environmental toxicology.

Woychik earned his Ph.D. in molecular biology in 1984 from Case Western Reserve University in Cleveland. He moved into the field of molecular genetics during postdoctoral training in the lab of the late Philip Leder, M.D., in Harvard Medical School Department of Genetics.

In 2010, he moved to NIEHS in the role of deputy director, bringing basic science expertise in using genetics and epigenetics to study the influence of the environment. Woychik successfully led strategic planning exercises and guided implementation across a broad range of scientific disciplines. In nearly a decade of leadership at NIEHS, he built an in-depth awareness of and appreciation for the broad range of scientific activities such as toxicology, epidemiology, and more that are necessary to effectively support the environmental health sciences community.

That experience contributes to the wealth of knowledge he brings to his new role. Prior to NIEHS, Woychik served nearly 10 years as president and CEO of The Jackson Laboratory in Bar Harbor, Maine, where he established a robust record of achievements.

Citations:Alagramam KN, Murcia CL, Kwon HY, Pawlowski KS, Wright CG, Woychik RP. 2001. The mouse Ames waltzer hearing-loss mutant is caused by mutation ofPcdh15, a novel protocadherin gene. Nat Genet. 27:99102.

Bultman SJ, Michaud EJ, Woychik RP. 1992. Molecular characterization of the mouse agouti locus. Cell 71(7):11951204.

Moyer JM, Lee-Tischler MJ, Kwon HY, Schrick JJ, Avner ED, Sweeney WE, Godfrey VL, Cacheiro NL, Wilkinson JE, Woychik RP. 1994. Candidate gene associated with a mutation causing recessive polycystic kidney disease in mice. Science 264:13291333.

(Christine Bruske Flowers is director of the NIEHS Office of Communications and Public Liaison.)

Read the original post:
July 2020: New NIEHS Director Rick Woychik will lead with innovation - Environmental Factor Newsletter

Posted in Molecular Genetics | Comments Off on July 2020: New NIEHS Director Rick Woychik will lead with innovation – Environmental Factor Newsletter

Page 937«..1020..936937938939..950960..»